Lipid-lowering, hepatoprotective, and atheroprotective effects of the mixture Hong-Qu and gypenosides in hyperlipidemia with NAFLD rats

Journal of the Chinese Medical Association

Volumn 79, Issue 3, 2016, Pages 111-121

  Gou, San Hu ^a   Huang, Hai Feng ^a   Chen, Xin Yue ^a   Liu, Jie ^b   He, Miao ^a   Ma, Yin Yun ^a   Zhao, Xiao Ning ^a   Zhang, Yun ^a   Ni, Jing Man ^a  

^a LANZHOU UNIVERSITY   (China)

^b GANSU PROVINCIAL HOSPITAL   (China)

Author keywords

Fermentum Rubrum; Gynostemma pentaphyllum; Gypenosides; Hong Qu; Hyperlipidemia; NAFLD

Indexed keywords

ACETYL COENZYME A CARBOXYLASE 1; BIOLOGICAL MARKER; CARNITINE PALMITOYLTRANSFERASE I; CHINESE DRUG; CHOLESTEROL; CYTOKINE; FATTY ACID SYNTHASE; GYPENOSIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HONG QU; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; JIAOGULAN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; MEVINOLIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ZHIBITUO; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME A; ACYL COENZYME A; ANTILIPEMIC AGENT; BIOLOGICAL PRODUCT; CHOLESTIN; PLANT EXTRACT; PROTECTIVE AGENT;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; FOAM CELL; GENE EXPRESSION; HYPERLIPIDEMIA; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIVER PROTECTION; LOW DRUG DOSE; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; RAT; ANIMAL; ATHEROSCLEROSIS; BLOOD; DRUG EFFECTS; GENETICS; GYNOSTEMMA; LIPID DIET; LIVER; METABOLISM; SPRAGUE DAWLEY RAT;

ACYL COENZYME A; ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL PRODUCTS; DIET, HIGH-FAT; GYNOSTEMMA; HYPOLIPIDEMIC AGENTS; LIPIDS; LIVER; MALE; PLANT EXTRACTS; PROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84960876767     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/j.jcma.2015.09.002     Document Type: Article

References (47)

1. Mahamuni S.P., Khose R.D., Menaa F., Badole S.L. Therapeutic approaches to drug targets in hyperlipidemia. BioMedicine 2012, 2:137-146.
2. Ruixing Y., Yuming C., Shangling P., Fengping H., Tangwei L., Dezhai Y., et al. Comparison of lipid levels, hyperlipidemia prevalence and its risk factors between Guangxi Hei Yi Zhuang and Han populations. Arch Med Res 2006, 37:787-793.
3. Nelson R.H. Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care 2013, 40:195-211.
4. Nascimbeni F., Pais R., Bellentani S., Day C.P., Ratziu V., Loria P., et al. From NAFLD in clinical practice to answers from guidelines. J Hepatol 2013, 59:859-871.
5. Lee J.H., Friso S., Choi S.W. Epigenetic mechanisms underlying the link between non-alcoholic fatty liver diseases and nutrition. Nutrients 2014, 6:3303-3325.
6. Anstee Q.M., Targher G., Day C.P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013, 10:330-344.
7. Koppe S.W.P. Obesity and the liver: nonalcoholic fatty liver disease. Transl Res 2014, 164:312-322.
8. Basaranoglu M., Ormeci N. Nonalcoholic fatty liver disease: diagnosis, pathogenesis, and management. Turk J Gastroenterol 2014, 25:127-132.
9. Hou R., Goldberg A.C. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety. Endocrin Metab Clin 2009, 38:79-97.
10. Musso G., Cassader M., Gambino R. Cholesterol-lowering therapy for the treatment of nonalcoholic fatty liver disease: an update. Curr Opin Lipidol 2011, 22:489-496.
11. Nseir W., Mahamid M. Statins in nonalcoholic fattyl iver disease and steatohepatitis: updated review. Curr Atheroscler Rep 2013, 15:1-6.
12. Sham T.T., Chan C.O., Wang Y.H., Yang J.M., Mok D.K.W., Chan S.W. A review on the traditional Chinese medicinal herbs and formulae with hypolipidemic effect. Biomed Res Int 2014, 2014:1153-1166.
13. Ma J.Y., Li Y.G., Ye Q., Li J., Hua Y.J., Ju D.J., et al. Constituents of red yeast rice, a traditional Chinese food and medicine. J Agric Food Chem 2000, 48:5220-5225.
14. Li X.M., Shen X.H., Duan Z.W., Guo S.R. Advances on the pharmacological effects of red yeast rice. Chin J Nat Med 2011, 9:161-166.
15. Xie X., Wang Y., Zhang S., Zhang G., Xu Y., Bi H., et al. Chinese red yeast rice attenuates the development of angiotensin II-induced abdominal aortic aneurysm and atherosclerosis. J Nutr Biochem 2012, 23:549-556.
16. Yang C.W., Mousa S.A. The effect of red yeast rice (Monascus purpureus) in dyslipidemia and other disorders. Complement Ther Med 2012, 20:466-474.
17. Childress L., Gay A., Zargar A., Ito M.K. Review of red yeast rice content and current Food and Drug Administration oversight. J Clin Lipidol 2013, 7:117-122.
18. Yuan Z.K., Wang D.S., Huang X.P., Guo Z.H., Lu F.G., Xie M.Z., et al. Experimental study of tablet Yangxintongmai on treatment for atherosclerosis. Symposium of China Postdoctors and Academicians on Life Science 2003, 392-399. Science Press Beijing, Peoples Rep. of China. J. xia (Ed.).
19. Xie W.D., Zhao Y.A., Du L.J. Emerging approaches of traditional Chinese medicine formulas for the treatment of hyperlipidemia. J Ethnopharmacol 2012, 140:345-367.
20. Guo M., Liu Y., Gao Z.Y., Shi D.Z. Chinese herbal medicine on dyslipidemia: progress and perspective. Evid-Based Complement Altern Med 2014, 2014:489-499.
21. Chen J., Deng J., Zhang Y., Yang J., He Y., Fu W., et al. Lipid-lowering effects of Danhong injection on hyperlipidemia rats. J Ethnopharmacol 2014, 154:437-442.
22. Wang Y.G., Fang W.L., Wei J., Wang T., Wang N., Ma J.L., et al. The involvement of NLRX1 and NLRP3 in the development of nonalcoholic steatohepatitis in mice. J Chin Med Assoc 2013, 76:686-692.
23. Bhattacharjee J., Kumar J.M., Arindkar S., Das B., Pramod U., Juyal R.C., et al. Role of immunodeficient animal models in the development of fructose induced NAFLD. J Nutr Biochem 2014, 25:219-226.
24. Iyer S., Upadhyay P.K., Majumdar S.S., Nagarajan P. Animal models correlating immune cells for the development of NAFLD/NASH. J Clin Exp Hepatol 2015, 5:239-245.
25. Ziamajidi N., Khaghani S., Hassanzadeh G., Vardasbi S., Ahmadian S., Nowrouzi A., et al. Amelioration by chicory seed extract of diabetes- and oleic acid-induced non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) via modulation of PPARα and SREBP-1. Food Chem Toxicol 2013, 58:198-209.
26. Patakova P. Monascus secondary metabolites: production and biological activity. J Ind Microbiol Biotechnol 2013, 40:169-181.
27. Cui J.F., Eneroth P., Bruhn J.G. Gynostemma pentaphyllum: identification of major sapogenins and differentiation from Panax species. Eur J Pharm Sci 1999, 8:187-191.
28. Huang T.H.W., Li Y.H., Razmovski-Naumovski V., Tran V.H., Li G.Q., Duke C.C., Roufogalis B.D. Gypenoside XLIX isolated from Gynostemma pentaphyllum inhibits nuclear factor-kappaB activation via a PPAR-alpha-dependent pathway. J Biomed Sci 2006, 13:535-548.
29. Loria P., Marchesini G., Nascimbeni F., Ballestri S., Maurantonio M., Carubbi F., et al. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. Atherosclerosis 2014, 232:99-109.
30. Tziomalos K., Athyros V.G. Fenofibrate: a novel formulation (Triglide (TM)) in the treatment of lipid disorders: a review. Int J Nanomed 2006, 1:129-147.
31. Isles C.G., Paterson J.R. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy. QJM 2000, 93:567-574.
32. Barter P. HDL-C: role as a risk modifier. Atheroscler Suppl 2011, 12:267-270.
33. Musso G., Gambino R., Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res 2009, 48:1-26.
34. Janero D.R. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radic Biol Med 1990, 9:515-540.
35. Aktan F., Henness S., Roufogalis B.D., Ammit A.J. Gypenosides derived from Gynostemma pentaphyllum suppress NO synthesis in murine macrophages by inhibiting iNOS enzymatic activity and attenuating NF-κB-mediated iNOS protein expression. Nitric Oxide 2003, 8:235-242.
36. Tanner M.A., Bu X., Steimle J.A., Myers P.R. The direct release of nitric oxide by gypenosides derived from the herb Gynostemma pentaphyllum. Nitric Oxide 1999, 3:359-365.
37. Burg J.S., Espenshade P.J. Regulation of HMG-CoA reductase in mammals and yeast. Prog Lipid Res 2011, 50:403-410.
38. Dentin R., Girard J., Postic C. Carbohydrate responsive element binding protein (ChREBP) and sterol regulatory element binding protein-1c (SREBP-1c): two key regulators of glucose metabolism and lipid synthesis in liver. Biochimie 2005, 87:81-86.
39. Kim Y.W., Kim Y.M., Yang Y.M., Kim T.H., Hwang S.J., Lee J.R., et al. Inhibition of SREBP-1c-mediated hepatic steatosis and oxidative stress by sauchinone, an AMPK-activating lignan in Saururus chinensis. Free Radic Biol Med 2010, 48:567-578.
40. Cintra D.E., Ropelle E.R., Vitto M.F., Luciano T.F., Souza D.R., Engelmann J., et al. Reversion of hepatic steatosis by exercise training in obese mice: the role of sterol regulatory element-binding protein-1c. Life Sci 2012, 91:395-401.
41. Pappenberger G., Benz J., Gsell B., Hennig M., Ruf A., Stihle M., et al. Structure of the human fatty acid synthase KS-MAT didomain as a framework for inhibitor design. J Mol Biol 2010, 397:508-519.
42. Igal R.A. Stearoyl-CoA desaturase-1: a novel key player in the mechanisms of cell proliferation, programmed cell death and transformation to cancer. Carcinogenesis 2010, 31:1509-1515.
43. Giby V.G., Ajith T.A. Role of adipokines and peroxisome proliferator-activated receptors in nonalcoholic fatty liver disease. World J Hepatol 2014, 6:570-579.
44. Van Raalte D.H., Li M., Pritchard P.H., Wasan K.M. Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future. Pharm Res 2004, 21:1531-1538.
45. Jia Y., Bhuiyan M.J.H., H-j Jun, Lee J.H., Hoang M.H., Lee H.J., et al. Ursolic acid is a PPAR-α agonist that regulates hepatic lipid metabolism. Bioorg Med Chem Lett 2011, 21:5876-5880.
46. Zarain-Herzberg A., Rupp H. Therapeutic potential of CPT I inhibitors: cardiac gene, transcription as a target. Expert Opin Investig Drugs 2002, 11:345-356.
47. Napal L., Marrero P.F., Haro D. an intronic peroxisome proliferator-activated receptor-binding sequence mediates fatty acid induction of the human carnitine palmitoyltransferase 1A. J Mol Biol 2005, 354:751-759.